Compass Therapeutics, Inc.
CMPX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.75
KIRA · Stoqly’s AI analyst, in plain words
- Compass Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Compass Therapeutics, Inc. lost $66.5M in fiscal 2025.
- Free cash flow was −$49.2M in fiscal 2025, — of revenue.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$66.5M
Free cash flow
−$49.2M
Operating margin
—
Compass Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$66.5M
No. It lost money last year.
What Compass Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Compass Therapeutics, Inc.
- CIK
- 0001738021
Compass Therapeutics, Inc. · CMPX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $0.9M | $0.0M |
| Revenue growth | — | — | — | — | −100.0% |
| Operating margin | — | — | — | −6,661.8% | — |
| Net income | −$82.2M | −$39.2M | −$42.5M | −$49.4M | −$66.5M |
| Net margin | — | — | — | −5,808.8% | — |
| Diluted EPS | −$1.31 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$19.7M | −$34.1M | −$40.6M | −$44.9M | −$49.1M |
| Capital expenditure | $1.6M | $0.2M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$21.2M | −$34.3M | −$40.6M | −$44.9M | −$49.2M |
| FCF margin | — | — | — | −5,282.2% | — |
| Share count change | 104.3% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $145M | $187M | $152M | $127M | $209M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $140M | $182M | $149M | $125M | $197M |
| Current ratio | 13.8x | 12.0x | 19.7x | 15.0x | 15.0x |
| Interest coverage | −221.3x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −91.3% | −24.4% | −25.7% | −36.1% | −41.3% |
| Return on tangible equity | −58.7% | −21.6% | −28.6% | −39.4% | −33.8% |
| Piotroski F-score | 4 | — | — | — | — |
| Altman Z'' | 8.0 | 10.6 | 16.1 | 3.3 | 6.3 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Compass Therapeutics, Inc. · CMPX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.75 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001738021). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.